Artemis II — A Tribute to the Brave Who Walk Toward the Future

Apollo was one of the defining achievements of the twentieth century, but it also left behind a strange inheritance. It proved that human beings could leave Earth, navigate across cislunar space, land on another world, and come home. Then, after proving it, the United States stopped going. The Moon remained in the cultural imagination, in schoolbooks, documentaries, museum halls, and old family conversations, but not in the rhythm of ordinary current events.

Firefly Aerospace ( $FLY ) Alpha Flight 7 worked

Firefly is easier to understand after March 2026 than it was a few months ago. Alpha Flight 7 reached orbit, delivered a Lockheed Martin payload, performed a stage-two relight, and validated key Block II upgrades ahead of Flight 8. That matters because the company badly needed a clean operational proof point after prior launch and test setbacks. The core story today is no longer “can Firefly do anything?” but “can Firefly string multiple wins together without burning too much cash along the way?”

Tilray Brands ( $TLRY ): Q3 FY2026 says the story is still alive

In early March, the core question around Tilray was not whether the company could tell a big story. It was whether that story was finally becoming tangible. Q3 FY2026 does not solve every doubt, but it does move the debate forward: cannabis improved, distribution stayed strong, margins held up better than feared, adjusted EBITDA grew, and the balance sheet still looks workable. The weak point remains the same one the market keeps circling around: beverage execution and the long shadow of dilution.

Sidus Space ( $SIDU )after Q4 2025: our thesis, what is being confirmed, and what still needs to be proven

Sidus Space has become one of those names that attract attention for a reason. It sits at the intersection of several powerful themes — small satellites, on-orbit processing, dual-use space and defense technology, edge AI, and the broader U.S. national-security buildout. But attractive themes alone are not enough. The real question for investors has always been simpler and harder at the same time: is Sidus merely assembling a compelling narrative, or is it actually building a business that can one day justify the story?

Omeros ( $OMER ): the post-approval story is finally turning, early commercial momentum is here, and the next upside chapter may be starting

The new March 31, 2026 press release did not simply deliver an earnings update. It effectively marked the first real post-approval checkpoint for Omeros. The company is no longer only a regulatory event story. After the December 23, 2025 FDA approval of YARTEMLEA for TA-TMA and the January 2026 U.S. launch, the central question has changed. The market is now asking whether the company can convert medical need, regulatory exclusivity and first-mover status into a durable commercial franchise.

Aquestive Therapeutics After the CRL ( $AQST ): what changed, what still matters, and how much balance-sheet room is left

Where the story stands today is more nuanced than the tape action around the January disappointment made it look. The FDA did not throw out the Anaphylm package because the drug failed on efficacy, because the core clinical bridge broke, or because major chemistry, manufacturing, and controls issues surfaced. The company’s February disclosure said the Complete Response Letter was focused on administration, labeling guidance, human factors deficiencies, and one supportive pharmacokinetic study tied to the packaging and labeling changes. In plain English, this was bad news, but it was not the same thing as a fundamental collapse of the program.

The market then needed a second question answered: would management actually get the FDA onto a defined remediation path, or would this turn into a vague, open-ended delay? The March 30 Type A meeting update is important because it is the first sign that the post-CRL process is becoming more concrete. AQST said the FDA gave clarifying feedback on both the PK and human factors study designs, acknowledged the changes to the pouch opening mechanism, and aligned on the concept of using labeling language to manage potential chewing of the film rather than demanding additional clinical data. That does not mean approval is in the bag. It does mean the company has moved from uncertainty to a more actionable playbook.

Polar Power Inc ( $POLA )

Polar Power, Inc. (NASDAQ: POLA) is a Gardena, California-based designer and manufacturer of direct current (DC) power generation systems serving telecommunications, military, commercial, and industrial markets globally.

As of the quarter ended September 30, 2025 and filed on November 19, 2025, POLA was in severe financial distress. Primary-source review confirms $4K cash, sharp year-over-year sales deterioration in Q3 2025, and material pressure on liquidity and financing. The original draft referenced a going concern warning from auditors, an eviction summons on the headquarters facility, lender covenant breach, and a $5.3M backlog. Of these, the cash position and broader distress are confirmed directly by the 10-Q; some of the more specific legal and audit formulations require direct supporting passages beyond what was fully retrieved in this review.

This remains a binary turnaround speculation, not an investment-grade opportunity. Execution on backlog, continued lender tolerance, and facility continuity could support survival. Failure on one or more of those fronts would materially increase restructuring or bankruptcy risk.

Agios Pharmaceuticals ( $AGIO ): the story did not end with the sickle-cell disappointment

Agios is not the same story it was one year ago, and it is not even the same story it was right after the market reacted badly to the November 2025 RISE UP data. The cleanest way to frame the company today is not as a single-product binary biotech and not as a fully de-risked rare-disease compounder either. It sits somewhere in the middle. There is now a real commercial base, a very strong balance sheet by biotech standards, a broader geographic footprint for mitapivat in thalassemia, and a reopened regulatory path in sickle cell disease that most investors had at least partially discounted after the mixed Phase 3 readout.

Sangamo Therapeutics ( $SGMO ) — Q4 2025 earnings, rolling BLA progress, cash pressure and dilution risk

Sangamo’s March 30, 2026 earnings release did not break the SGMO story. It clarified it. The company still has one asset that can genuinely change perception — ST-920 in Fabry disease — and one problem that can still overwhelm everything else — money. The clinical and regulatory side remains credible enough to keep the name alive. The balance sheet remains weak enough to keep common shareholders on a short leash.

Virgin Galactic (SPCE): why the stock jumped after earnings, what the March 30 update really changed, and what the market will watch next

Virgin Galactic’s after-hours rebound was not about a sudden return to revenue. It was about a cleaner execution story: ticket sales reopened at $750,000 per seat, the first of the new SpaceShips is moving into ground testing in April, flight testing is still targeted for Q3 2026, commercial operations remain on track for Q4 2026, and the second ship is now framed for service between late Q4 2026 and early Q1 2027. In a stock as depressed and timeline-sensitive as SPCE, that combination was enough to trigger a sharp relief move.

Encyclopedia of Social Trader Myths – Vol. 3The Self-Inflicted Edition

trading myths3

The first myths of social trading usually come from outside: the trending ticker, the guru thread, the magical catalyst calendar, the cult of “smart money,” the promise that one more breakout will fix your year. But the deeper myths are the private ones. They appear after the chart turns ugly, after the timing fails, after the confidence starts cracking. That is when the internal narrator goes to work.

This third volume is about those myths. Not the noisy lies from the feed, but the polished lies traders tell themselves when they need to protect pride, postpone discomfort, and keep a bad trade emotionally alive for just a little longer. These myths sound reasonable in real time. That is exactly why they are dangerous.

Summit Therapeutics (SMMT): ELCC 2026 posters, stronger cash, and why retail is trying to rebuild the ivonescimab story

The latest Summit update does not magically erase the old debate around overall survival, but it does add new material that retail traders and long-form biotech readers can use to reframe the case: deeper intracranial data, quality-of-life support, a visible FDA date, and a balance sheet that gives the company room to keep pushing an unusually broad ivonescimab program.

Golden Dome is no longer just a slogan: where the first real money may go

Golden Dome now looks less like a pure political slogan and more like the early framework of a real spending cycle. The most important development is not that the U.S. wants a giant missile shield in the abstract. It is that the discussion has become more operational: estimated cost has moved higher, specific capability layers have been identified for acceleration, and Reuters reported that Anduril and Palantir are working on the software layer while traditional primes such as Lockheed Martin, RTX and Northrop Grumman are involved on the industrial side.

Viridian Therapeutics ( $VRDN ): why the stock crashed on “positive” REVEAL-1 data

Viridian’s REVEAL-1 press release was positive in the narrow, technical sense that matters most for binary biotech trading: the phase 3 trial hit its primary endpoint. Elegrobart, the company’s subcutaneous IGF-1R antibody for active thyroid eye disease, delivered a 54% proptosis responder rate in the every-four-week arm and 63% in the every-eight-week arm, versus 18% on placebo. The Q4W arm also showed strong diplopia data, including 51% complete resolution versus 16% on placebo. That is not failure language. That is a live asset with real activity. And yet the stock was hit as if something had gone badly wrong.

Lithium Americas ( $LAC ) DD march 30 2026

Lithium Americas is no longer a story that should be read like a generic lithium exploration name. At this stage, it is much closer to a highly leveraged construction-and-financing story centered on one asset, one timetable, and one capital structure: Thacker Pass in Nevada. The company has already crossed the part of the curve where the market mainly debates whether the resource is real. That is not the core issue anymore. The resource and reserve base is already large enough to make the project strategically important, and the company now frames Thacker Pass as the largest known measured-and-indicated lithium resource and proven-and-probable reserve in the world. The market’s real question is simpler and more brutal: can management convert that geological scale into an operating business without losing control of timing, cost, or shareholder dilution?

Replimune ( $REPL) • Biotech • Oncolytic Immunotherapy

Replimune is not a “nice little pipeline story” going into spring 2026. It is a high-beta, high-volatility, very real binary event name whose valuation, narrative, financing flexibility, and strategic credibility are all tied in a major way to one date: April 10, 2026. That is the FDA target action date for the resubmitted BLA for RP1 plus nivolumab in advanced melanoma after anti-PD-1 failure. The market already treated the October 2025 acceptance of the resubmission as a major event, and for good reason. This was not a routine update. It was the market’s signal that the story had gone from post-CRL damage control back to live regulatory possibility.

Altimmune ( $ALT ) May Be One of the Last Shots on Goal in the Obesity-MASH Convergence 2026

After Breakthrough Therapy Designation, 48-week IMPACT data, a financing reset and a clearer 2026 roadmap, the real question is no longer whether Altimmune can generate attention. The real question is whether pemvidutide still deserves to be viewed as one of the last relatively clean independent shots on goal at the intersection of obesity, MASH and broader metabolic-liver disease.

Perfectly Timed Trades Before Trump’s Moves . Coincidences or an Information Leak in the Market?

In recent days, Reuters pulled together a series of episodes that, taken one by one, could look like simple strokes of luck. Seen together, however, they tell a more troubling story: extremely well-timed financial trades placed shortly before political decisions or geopolitical developments tied to the White House and capable of generating very large profits in futures, options and prediction markets.

Reuters says it has not proved a direct link between those traders and the Trump administration, but it also says the pattern is serious enough to raise hard questions and to warrant regulatory attention. That distinction matters. The story is not that wrongdoing has been proved. The story is that the timing has become too precise, too repeated and too profitable to be brushed away casually.

Nektar Therapeutics ( $NKTR ): a full deep dive March 29 2026

Nektar has gone from being, for years, a biotech many investors considered tired and heavily scarred to one of the most discussed U.S. biotech stories of 2025–2026. The reason is not empty narrative. It is the combination of the clinical relaunch of rezpegaldesleukin, two dermatology indications that reignited attention, a balance sheet materially strengthened after the large February 2026 financing, and a pipeline that, while still far from commercial stage, now looks much more readable than it did just twelve months ago.